Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05717738
- Locations
- 🇨🇳
Optical Valley branch of Tongji hospital, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Wan-Guang Zhang
- Target Recruit Count
- 300
- Registration Number
- NCT05713994
- Locations
- 🇨🇳
TongjiHospital, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 12
- Registration Number
- NCT05669339
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT05601895
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 37
- Registration Number
- NCT05596968
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT05596981
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Conditions
- Interventions
- Drug: PIK3CA inhibitorDrug: AKT inhibitorDrug: SHR-A1811Drug: CarrelizumabDrug: SHR-1167Drug: FamitinibDrug: SorafenibDrug: EverolimusDrug: FluzoparibDrug: Aromatase Inhibitors or FulvestrantDrug: TPCDrug: SHR-A1921Drug: SHR-6209Drug: DalpiciclibDrug: ApatinibDrug: SHR-A2009Drug: SHR-A2102Drug: GoserelinDrug: bevacizumab
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT05468359
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 88
- Registration Number
- NCT05404516
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 43
- Registration Number
- NCT05313958
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.